Evolus, Inc. Stock News

Our portfolios underperformed during the quarter and trail year to date. Health care was the primary hindrance as a result of our underweight in biotech and negative stock selection. We have materially decreased our position as we evaluate this specific risk.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in November of non-qualified stock options to purchase an aggregate of 17,871 shares of Evolus and an aggregate of 45,063 restricted stock units (RSUs) of the company's common stock to 13 newly hired non-ex...

Evolus, Inc. ( EOLS ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Nareg Sagherian - Head of Global Investor Relations & Corporate Communications David Moatazedi - President, CEO & Director Rui Avelar - Chief Medical Officer and Head of Research & Development Tatjana Mitchell - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel, Nicolaus & Co...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the third quarter ended September 30, 2025. “Our third quarter results reflect double-digit growth despite the current market environment. Our continued above market performance and discipl...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Stifel Healthcare Conference. The fireside chat will take place on Tuesday, November 11, 2025, at 11:20 AM ET....

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2025 financial results on Wednesday, November 5, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these re...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in October of non-qualified stock options to purchase an aggregate of 24,931 shares of Evolus and an aggregate of 31,116 restricted stock units (RSUs) of the company's common stock to 9 newly hired non-exec...

Headline Summary: Board-certified plastic surgeon brings extensive expertise in facial anatomy and injectable treatments to support nationwide rollout of breakthrough hyaluronic acid technology. Partnership underscores Evolus' commitment to patient safety and provider education for their new FDA-approved filler line.